A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
Open Access
- 1 July 2016
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 21 (3) , 407-416
Abstract
Background Tenapanor (RDX5791, AZD1722), a small molecule with minimal systemic availability, is an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3). Tenapanor acts locally in the gut to reduce absorption of sodium and phosphate. It is being developed for the treatment of patients with hyperphosphatemia in CKD requiring dialysis and patients with constipation-predominant irritable bowel syndrome. We report the safety, pharmacodynamics, and pharmacokinetics of tenapanor in Japanese volunteers. Methods In this phase 1, double-blind study (NCT02176252), healthy Japanese adults (aged 20–45 years) received single-dose tenapanor 180 mg (n = 6), repeated-dose tenapanor 15, 30, 60, or 90 mg twice daily (n = 12 each) for 7 days, or placebo (n = 14). All participants received a standardized diet. Results Single and repeated doses of tenapanor resulted in higher mean stool sodium content vs. placebo (single dose, 41.9 mmol/day; repeated dose, range of means 21.3–32.2 mmol/day; placebo, 4.1 mmol/day) accompanied by lower urinary sodium content (single dose, 110 mmol/day; repeated dose, 101–112 mmol/day; placebo, 143 mmol/day). Additionally, stool phosphorus content was increased (single dose, 31.0 mmol/day; repeated dose, 17.6–24.8 mmol/day; placebo, 16.8 mmol/day) and urinary phosphorus content decreased (single dose, 18.7 mmol/day; repeated dose, 15.3–19.4 mmol/day; placebo, 25.5 mmol/day). Tenapanor had minimal systemic exposure, provided a softer stool consistency, and was well tolerated. Conclusions Tenapanor treatment reduced absorption of intestinal sodium and phosphate from the gut in Japanese adults. Tenapanor had minimal systemic exposure and was well tolerated. Further research into the clinical benefits of tenapanor is warranted.Keywords
Funding Information
- AstraZeneca
This publication has 28 references indexed in Scilit:
- Sodium, Blood Pressure, and Cardiovascular DiseaseCirculation, 2012
- The Importance of Population-Wide Sodium Reduction as a Means to Prevent Cardiovascular Disease and StrokeCirculation, 2011
- Fluid Retention Is Associated With Cardiovascular Mortality in Patients Undergoing Long-Term HemodialysisCirculation, 2009
- High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patientsNephrology Dialysis Transplantation, 2007
- MOLECULAR PHYSIOLOGY OF INTESTINAL N+/H+ EXCHANGEAnnual Review of Physiology, 2005
- Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2004
- Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2004
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- Calcium, Phosphate, and Parathyroid Hormone Levels in Combination and as a Function of Dialysis Duration Predict MortalityJournal of the American Society of Nephrology, 2004
- Stool Form Scale as a Useful Guide to Intestinal Transit TimeScandinavian Journal of Gastroenterology, 1997